adipose tissue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Progesterone is a naturally occurring pregnane steroid and is also known as pregn-4-ene-3,20-dione. It has a double bond (4-ene) between the C4 and C5 positions and two ketone groups (3,20-dione), one at the C3 position and the other at the C20 position. Due to its pregnane core and C4(5) double bond, progesterone is often abbreviated as P4. It is contrasted with pregnenolone, which has a C5(6) double bond and is often abbreviated as P5.
=== Toughness and hysteresis === The toughness of a hydrogel refers to the ability of the hydrogel to withstand deformation or mechanical stress without fracturing or breaking apart. A hydrogel with high toughness can maintain its structural integrity and functionality under higher stress. Several factors contribute to the toughness of a hydrogel including composition, crosslink density, polymer chain structure, and hydration level. The toughness of a hydrogel is highly dependent on what polymer(s) and crosslinker(s) make up its matrix as certain polymers possess higher toughness and certain crosslinking covalent bonds are inherently stronger. Additionally, higher crosslinking density generally leads to increased toughness by restricting polymer chain mobility and enhancing resistance to deformation. The structure of the polymer chains is also a factor in that, longer chain lengths and higher molecular weight leads to a greater number of entanglements and higher toughness. A good balance (equilibrium) in the hydration of a hydrogel leads is important because too low hydration causes poor flexibility and toughness within the hydrogel, but too high of water content can cause excessive swelling, weakening the mechanical properties of the hydrogel.
Misdiagnoses can lead physicians to order biopsies, potentially exacerbating the growth of FOP bone. The presence of malformed toes or thumbs in those born with FOP helps distinguish this disorder from other skeletal problems. With proper medical management the median age of survival is 40 years. However, delayed diagnosis, trauma, and infections can decrease life expectancy.
Sources: en.wikipedia.org
Mikhail Semyonovich Tsvet, also spelt Tsvett, Tswett, Tswet, Zwet, and Cvet (Russian: Михаил Семёнович Цвет; 14 May 1872 – 26 June 1919) was a Russian-Italian botanist who invented chromatography. His last name is Russian for "colour" and is also the root word of "flower."
White tried to use taking more pictures as an excuse to stay out longer, and McDivitt had to coax him in. He finally came back in after a total of approximately 23 minutes, almost 10 minutes later than was planned. He said: "It's the saddest moment of my life." By the time he got in, the spacecraft had entered darkness. The hatch proved to be as stubborn to relatch as it was to open. This would have been disastrous, resulting in both men's deaths on reentry. McDivitt was able to fix the mechanism once again, so White could close it, about 20 minutes after he got in. The mission plan called for opening the hatch again to throw out White's now-unnecessary EVA equipment, but McDivitt elected not to do this, instead keeping the unnecessary equipment on board for the rest of the flight. They powered down the spacecraft's maneuvering system, intending to drift for the next two-and-a-half days to conserve the remaining fuel. They also intended to sleep alternate four-hour periods, but this turned out to be extremely difficult with the constant radio communications and the small cabin, about the size of the front seats of a compact car. White's 20-minute space walk was the mission's highlight, with McDivitt's photographs being published worldwide. These also showed White wearing an Omega Speedmaster chronograph watch on his spacesuit sleeve, one of two makes which had been approved by NASA for space use following extensive tests. Omega were unaware of these tests or the fact that its product was going to be used in space, until the photos.
=== Insulin biosynthesis and transcription === Insulin biosynthesis is regulated by transcriptional and translational levels. The β-cells promote their protein transcription in response to nutrients. The exposure of rat Langerhans islets to glucose for 1 hour is able to remarkably induce the intracellular proinsulin levels. It was noted that the proinsulin mRNA remained stable. This suggests that the acute response to glucose of the insulin synthesis is independent of mRNA synthesis in the first 45 minutes because the blockage of the transcription decelerated the insulin accumulation during that time. PTBPs, also called polypyrimidine tract binding proteins, are proteins that regulate the translation of mRNA. They increase the viability of mRNA and provoke the initiation of the translation. PTBP1 enable the insulin gene-specific activation and insulin granule protein mRNA by glucose. Two aspects of the transduction pathway process are explained below: insulin secretion and insulin action on the cell.
Sources: en.wikipedia.org
Gankyrin, a recently identified oncoprotein, is one of the 19S subcomponents that also tightly binds the cyclin-dependent kinase CDK4 and plays a key role in recognizing ubiquitinated p53, via its affinity for the ubiquitin ligase MDM2. Gankyrin is anti-apoptotic and has been shown to be overexpressed in some tumor cell types such as hepatocellular carcinoma. Like eukaryotes, some archaea also use the proteasome to control cell cycle, specifically by controlling ESCRT-III-mediated cell division.
== See also == AXIN1 GSK-3 Management of hair loss Wingless localisation element 3 (WLE3) WNT1-inducible-signaling pathway protein 1 (WISP1) WNT1-inducible-signaling pathway protein 2 (WISP2) WNT1-inducible-signaling pathway protein 3 (WISP3)
=== Evacuation of Kabul === In August 2021, elements of the 82nd Airborne Division, particularly the Immediate Response Force, deployed to Afghanistan to secure the evacuation of American diplomats and Afghan Special Immigrant Visa applicants as the Taliban seized land and converged on Kabul. Throughout Operation Allies Refuge, the 82nd Airborne Division served as the Operational Command, Task Force 82. Operation Allies Refuge, led by Major General Chris Donahue, was a combined and joint NATO command post composed of forces representing NATO allied Nations, 1st Brigade Combat Team "Devil", aviation capabilities from the 82nd Combat Aviation Brigade "Pegasus", medical capabilities from the 44th Medical Brigade, riot control capabilities from the 16th Military Police Brigade, 24th Marine Expeditionary Unit, and the 3rd Expeditionary Sustainment Command who oversaw sustainment in the joint operational area from a command post in Kuwait.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.